Investor Relations

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.


All Releases
View Summary PTC Therapeutics to Present at the Credit Suisse 23rd Annual Healthcare Conference
Oct 29, 2014
PDF 7.2 KB Add to Briefcase
View Summary Translarna™ Phase 2b Data Published in Muscle & Nerve
Oct 27, 2014
PDF 61.8 KB Add to Briefcase
View Summary PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2014 Financial Results
Oct 23, 2014
PDF 8.5 KB Add to Briefcase
View Summary PTC Therapeutics Announces Pricing of Public Offering of Common Stock
Oct 9, 2014
PDF 45.4 KB Add to Briefcase
View Summary PTC Therapeutics Announces Proposed Public Offering of Common Stock
Oct 8, 2014
PDF 45.5 KB Add to Briefcase
View Summary PTC Therapeutics to Present at the Leerink Partners Rare Disease Roundtable
Sep 24, 2014
PDF 43.5 KB Add to Briefcase
View Summary PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635©(4)
Sep 24, 2014
PDF 43.6 KB Add to Briefcase
View Summary PTC Therapeutics Expands Global Presence in Support of Translarna™ Launch in Duchenne Muscular Dystrophy
Sep 17, 2014
PDF 84.2 KB Add to Briefcase
View Summary PTC THERAPEUTICS COMPLETES ENROLLMENT OF LANDMARK TRIAL IN DUCHENNE MUSCULAR DYSTROPHY
Sep 9, 2014
PDF 11.1 KB Add to Briefcase
View Summary PTC THERAPEUTICS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES
Aug 20, 2014
PDF 6.8 KB Add to Briefcase
View Summary PTC Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Aug 7, 2014
PDF 57.4 KB Add to Briefcase
View Summary Orally delivered compounds, which selectively modify RNA splicing prevent deficits in mouse models of Spinal Muscular Atrophy
Aug 7, 2014
PDF 11.7 KB Add to Briefcase
View Summary PTC Therapeutics Receives Conditional Approval in the European Union for Translarna For the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy
Aug 4, 2014
PDF 11.2 KB Add to Briefcase
View Summary PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635©(4)
Aug 1, 2014
PDF 6.9 KB Add to Briefcase
View Summary PTC Therapeutics to Present at the Wedbush Life Sciences Management Access Conference
Jul 30, 2014
PDF 6.5 KB Add to Briefcase
View Summary PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results
Jul 24, 2014
PDF 6.6 KB Add to Briefcase
View Summary PTC Therapeutics Announces Expanded Access Program For Translarna (ataluren)
Jul 9, 2014
PDF 10.4 KB Add to Briefcase
View Summary PTC THERAPEUTICS INITIATES CONFIRMATORY PHASE 3 CLINICAL TRIAL OF TRANSLARNA (ATALUREN) IN PATIENTS WITH NONSENSE MUTATION CYSTIC FIBROSIS (NMCF)
Jun 30, 2014
PDF 11.7 KB Add to Briefcase
View Summary PTC THERAPEUTICS RECIPIENT OF PARENT PROJECT MUSCULAR DYSTROPHY'S "PATH TO PROGRESS" AWARD
Jun 30, 2014
PDF 8.6 KB Add to Briefcase
View Summary PTC THERAPEUTICS TO PRESENT AT THE 9TH ANNUAL JMP SECURITIES HEALTHCARE CONFERENCE
Jun 17, 2014
PDF 6.5 KB Add to Briefcase
Showing 1-20 of 88 Page: 1 2 3 4 5  Next 20
Add to Briefcase = add release to Briefcase